Sjögren's disease & overlap diseases
Treatment and follow-up of patients with Sjögren's disease associated interstitial lung disease: a case series
Authors' conclusion
SjD-ILD clinical course is variable, with the most aggressive form to be controlled by immunosuppressive treatment.
Study context
- Population
- Primary SjD-ILD patients (interstitial lung disease (ILD) on HRCT per Fleischner Society definitions), followed up October 2022 to June 2025
- Participants
- 24 patients
- Exposure
- Treatment for ILD vs watch-and-wait
- Treatedn = 12
- Untreatedn = 12reference
- Outcome
- Progression of ILD (absolute decline of predicted FVC ≥5%)
- Follow-up
- 24±6 months
Methodological detailswatch-and-wait comparison group, treatment allocation by clinical judgement
- Watch-and-wait comparison group
- Treatment allocation by clinical judgement
Main finding
As reported in the abstract
Progression of ILD (absolute FVC decline ≥5%)
P = 0.999
Observational data: associations, not effects.
Further findings
Baseline small airways disease on HRCT
P = 0.027
| Outcome | Treated | Untreated | P value |
|---|---|---|---|
| Change in DLCO between visits · 24±6 monthsWorse in treated · mean | −11.2% | 4.8% | P = 0.003 |
| Baseline extent of ILD on HRCTMedian | 20% | 10% | P = 0.006 |
| Baseline FVC (% predicted)Tended to be lower · mean | 81.3% | 96.7% | P = 0.086 |
Forced vital capacity (FVC) and DLCO, baseline to follow-up · 24±6 months
- Remained stable in both groups
Original publication
Treatment and follow-up of patients with Sjögren's disease associated interstitial lung disease: a case series. Clin Exp Rheumatol. Published 19 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →